Novo Nordisk Investments & Fund Profile

Overview

Healthcare company producing insulin and diabetes treatments.

Founded

1923

Deals · 12mo

0

Links

Website LinkedIn X (Twitter)

Stage focus

Series B

Series C

Series D

Geographic focus

Canada

Denmark

Germany

United Kingdom

...

Sector focus

Biotechnology

Health Care

Medical

Pharmaceutical

Investment portfolio

12rounds

LedParticipated

NAME	DATE	SIZE
Aspect Biosystems	Jan 2025Participated	$115 MSeries B
ElevateBio	May 2023Participated	$401 MSeries D
Amalgam Rx	Jan 2023Led	$17 MSeries A
Beta Bionics	Feb 2022Participated	$57 MSeries C
Glooko	Mar 2021Participated	$30 MSeries D
Sundew	Sep 2020Led	$2 MSeed
Oxford BioMedica	May 2019Led	$68 MOther Equity
Beta Bionics	Sep 2018Participated	$50 MSeries B
Affimed	Sep 2014Led	$29 MSeries E
Affimed	Oct 2012Led	$20 MSeries D
Affimed	Apr 2010Led	$27 MSeries C
Pieris AG	Mar 2008Led	$39 MSeries B
Aspect Biosystems	Jan 2025Participated	$115 MSeries B
ElevateBio	May 2023Participated	$401 MSeries D
Amalgam Rx	Jan 2023Led	$17 MSeries A
Beta Bionics	Feb 2022Participated	$57 MSeries C
Glooko	Mar 2021Participated	$30 MSeries D
Sundew	Sep 2020Led	$2 MSeed
Oxford BioMedica	May 2019Led	$68 MOther Equity
Beta Bionics	Sep 2018Participated	$50 MSeries B
Affimed	Sep 2014Led	$29 MSeries E
Affimed	Oct 2012Led	$20 MSeries D
Affimed	Apr 2010Led	$27 MSeries C
Pieris AG	Mar 2008Led	$39 MSeries B

12 Items

12

Items

Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Novo Nordisk: 12 funding rounds are recorded in the selected participation categories. All available history
Round type	Led deals	Participated deals
Seed	1	0
Series A	1	0
Series B	1	2
Series C+	3	3
Other Equity	1	0

Monthly Deal Activity

Novo Nordisk: 12 deals are recorded across 224 months. All available history
Month	Deals
Mar '08	1
Apr '08	0
May '08	0
Jun '08	0
Jul '08	0
Aug '08	0
Sep '08	0
Oct '08	0
Nov '08	0
Dec '08	0
Jan '09	0
Feb '09	0
Mar '09	0
Apr '09	0
May '09	0
Jun '09	0
Jul '09	0
Aug '09	0
Sep '09	0
Oct '09	0
Nov '09	0
Dec '09	0
Jan '10	0
Feb '10	0
Mar '10	0
Apr '10	1
May '10	0
Jun '10	0
Jul '10	0
Aug '10	0
Sep '10	0
Oct '10	0
Nov '10	0
Dec '10	0
Jan '11	0
Feb '11	0
Mar '11	0
Apr '11	0
May '11	0
Jun '11	0
Jul '11	0
Aug '11	0
Sep '11	0
Oct '11	0
Nov '11	0
Dec '11	0
Jan '12	0
Feb '12	0
Mar '12	0
Apr '12	0
May '12	0
Jun '12	0
Jul '12	0
Aug '12	0
Sep '12	0
Oct '12	1
Nov '12	0
Dec '12	0
Jan '13	0
Feb '13	0
Mar '13	0
Apr '13	0
May '13	0
Jun '13	0
Jul '13	0
Aug '13	0
Sep '13	0
Oct '13	0
Nov '13	0
Dec '13	0
Jan '14	0
Feb '14	0
Mar '14	0
Apr '14	0
May '14	0
Jun '14	0
Jul '14	0
Aug '14	0
Sep '14	1
Oct '14	0
Nov '14	0
Dec '14	0
Jan '15	0
Feb '15	0
Mar '15	0
Apr '15	0
May '15	0
Jun '15	0
Jul '15	0
Aug '15	0
Sep '15	0
Oct '15	0
Nov '15	0
Dec '15	0
Jan '16	0
Feb '16	0
Mar '16	0
Apr '16	0
May '16	0
Jun '16	0
Jul '16	0
Aug '16	0
Sep '16	0
Oct '16	0
Nov '16	0
Dec '16	0
Jan '17	0
Feb '17	0
Mar '17	0
Apr '17	0
May '17	0
Jun '17	0
Jul '17	0
Aug '17	0
Sep '17	0
Oct '17	0
Nov '17	0
Dec '17	0
Jan '18	0
Feb '18	0
Mar '18	0
Apr '18	0
May '18	0
Jun '18	0
Jul '18	0
Aug '18	0
Sep '18	1
Oct '18	0
Nov '18	0
Dec '18	0
Jan '19	0
Feb '19	0
Mar '19	0
Apr '19	0
May '19	1
Jun '19	0
Jul '19	0
Aug '19	0
Sep '19	0
Oct '19	0
Nov '19	0
Dec '19	0
Jan '20	0
Feb '20	0
Mar '20	0
Apr '20	0
May '20	0
Jun '20	0
Jul '20	0
Aug '20	0
Sep '20	1
Oct '20	0
Nov '20	0
Dec '20	0
Jan '21	0
Feb '21	0
Mar '21	1
Apr '21	0
May '21	0
Jun '21	0
Jul '21	0
Aug '21	0
Sep '21	0
Oct '21	0
Nov '21	0
Dec '21	0
Jan '22	0
Feb '22	1
Mar '22	0
Apr '22	0
May '22	0
Jun '22	0
Jul '22	0
Aug '22	0
Sep '22	0
Oct '22	0
Nov '22	0
Dec '22	0
Jan '23	1
Feb '23	0
Mar '23	0
Apr '23	0
May '23	1
Jun '23	0
Jul '23	0
Aug '23	0
Sep '23	0
Oct '23	0
Nov '23	0
Dec '23	0
Jan '24	0
Feb '24	0
Mar '24	0
Apr '24	0
May '24	0
Jun '24	0
Jul '24	0
Aug '24	0
Sep '24	0
Oct '24	0
Nov '24	0
Dec '24	0
Jan '25	1
Feb '25	0
Mar '25	0
Apr '25	0
May '25	0
Jun '25	0
Jul '25	0
Aug '25	0
Sep '25	0
Oct '25	0
Nov '25	0
Dec '25	0
Jan '26	0
Feb '26	0
Mar '26	0
Apr '26	0
May '26	0
Jun '26	0
Jul '26	0
Aug '26	0
Sep '26	0
Oct '26	0

Sector Breakdown

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Novo Nordisk: Health & Life Sciences is the largest displayed sector by deal count (12 deals). All available history
Sector	Deals
Health & Life Sciences	12
Enterprise Software	2
Food & Agriculture	1
AI & Machine Learning	1
Data, Analytics & IT	1

Deal Size Distribution

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Novo Nordisk: 12 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)	Deals
<$5M	1
$5M-$10M	0
$10M-$25M	2
$25M-$50M	4
$50M-$100M	3
$100M-$250M	1
$250M-$500M	1
$500M-$1B	0
$1B+	0

Deals By Geography

Top 3 of 3 regions; European countries are grouped as Europe.

Novo Nordisk: Europe has the largest recorded deal count among the displayed regions (6 deals). All available history
Region	Deals
Europe	6
United States	5
Canada	1

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Novo Nordisk: 20 co-investors are shown, with OrbiMed sharing 4 recorded deals. All available history
Co-investor	Shared deals
OrbiMed	4
Aeris Capital	3
BioMedPartners	3
EQT Life Sciences (LSP)	3
Eventide Asset Management	2
Perceptive Advisors	2
RTW Investments	2
ArrowMark Partners	1
AyurMaya	1
Canaan Partners	1
DIMENSION	1
EcoR1 Capital	1
EDBI	1
Emerson Collective	1
F2 Ventures	1
Farallon Capital Management	1
Fidelity Management & Research Company	1
Forbion	1
Georgian Partners	1
Gilde Healthcare	1